News & Events
October 02 2018

NICE Today recommend
iFuse for treating chronic
sacroiliac joint pain

['NICE Today recommend\r', 'iFuse for treating chronic\r', 'sacroiliac joint pain']

The National Institute for Health and Care Excellence (NICE) Have today recommended the adoption of the iFuse device by Si-Bone, a Device Access Client.

The case for adopting the iFuse implant system to treat chronic sacroiliac joint pain is supported by the evidence. Using iFuse leads to improved pain relief, better quality of life and less disability compared with non-surgical management.

iFuse should be considered for use in people with a confirmed diagnosis of chronic sacroiliac joint pain (based on clinical assessment and a positive response to a diagnostic injection of local anaesthetic in the sacroiliac joint) and whose pain is inadequately controlled by non-surgical management.

Cost modelling indicates that after 8 years, using iFuse instead of non-surgical management will save the NHS around £129 per patient. It is likely that savings will then increase over time. Savings mainly come from fewer steroid joint injections and less pain relief medication with iFuse compared with non-surgical management.

About the Si-Bone iFuse technology

The iFuse implant system (SI‑Bone) is a titanium implant intended for use in people with chronic sacroiliac joint pain. iFuse is placed across the sacroiliac joint using minimally invasive surgery, where it is intended to stabilise the joint and to correct any misalignment or weakness that can cause chronic pain. The implant is triangular, which is designed to limit movement and spread shear stresses evenly. It has a porous metal coating, which the company claims promotes bone-on-bone growth and encourages joint fusion. Typically, 3 implants are used per joint, depending on the size of the pelvis. Implanting iFuse is a technically challenging procedure for which surgeons need specific training (provided at no additional cost by the company).

The cost of iFuse stated in the company’s submission is £4,059, which includes 3 implants and the necessary consumables for the procedure. The cost of theatre time is estimated to be £1,310 per procedure (using HRG code HN13A‑F – Major hip procedures from NHS reference costs for 2015/16).

The claimed benefits in the case for adoption presented by the company are listed in the scope of this evaluation.

Chronic sacroiliac joint pain can affect people of any age and usually needs lifelong management. The standard of care is escalating non-surgical management, typically beginning with analgesic therapy (such as non-steroidal anti-inflammatory drugs or opioids) combined with physiotherapy. If these initial treatments are ineffective, invasive procedures may be considered. These include steroid injections into the sacroiliac joint itself and radiofrequency ablation to the nerves that supply the joint. Sacroiliac joint fusion may be considered if the chronic pain continues. This can be done through open surgery or through a minimally invasive procedure, using a device such as iFuse. Invasive procedures and surgical treatments for chronic sacroiliac joint pain are usually done by spinal surgeons and orthopaedic trauma pelvic surgeons working in specialist centres.

To find out more visit the NICE Website HERE

Please contact Device Access – info@deviceaccess.co.uk to find out how we can help you successfully engage with NICE.

Most recent
The Power of the Patient's Voice in NHS MedTech Adoption
July 16 2020
What is NICE Recommendation and Why is it Useful?
July 10 2020
What is MedTech Market Access?
June 04 2020
Planning Your Engagement Strategy with the NHS Post-Covid-19
June 04 2020
“Battle Stations”: MedTech Can Fight Against Unseen Enemies Like Covid-19
April 02 2020
MedTech Industry Engagement with NHS England after Covid-19
March 20 2020
New NHS England MedTech Funding Mandate Proposal – to get innovative medical devices, diagnostics and digital products to patients faster
November 16 2019
Innovative Approach That Gets Patients Back Into Their Own Homes After Hospital Stay Honoured - NHS England
July 25 2019
Health Technology Evaluation Methods
July 23 2019
NHS England Medical Device Reimbursement Opportunities
July 01 2019
NICE Guidance for High Performing MedTech Products an Accelerated Access Scheme
May 02 2019
IGES Institut GmbH Acquires Majority Shareholding in Device Access UK
March 04 2019
NICE Approves New Minimally Invasive Steam Ablation Treatment for Benign Prostatic Hyperplasia
August 21 2018
Device Access CEO Presenting at NIHR Surgical MedTech Cooperative National Meeting 2018 – Leeds Wednesday 7th November 2018
October 02 2018
Device Access CEO Presenting at 2018 MedTech Reimbursement Roundtable Zurich Tuesday October 30th
October 02 2018
NICE Today recommend iFuse for treating chronic sacroiliac joint pain
October 02 2018
NHS England is Calling on the Best Innovators from Across the World to Apply to Join New NHS Adoption Scheme to Ensure Patients Benefit from New Technology Faster.
September 14 2018
Device Acccess is Attending Medical Alley Innovation Summit October 2nd 2018
September 06 2018
Device Access Attending Advamed Philadelphia 24th-27th September 2018
August 22 2018
Contact us